News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ilypsa, Inc. Completes Enrollment of Phase 2 Clinical Trial of ILY101 For Patients With Chronic Kidney Disease On Hemodialysis


2/6/2007 11:48:40 AM

SANTA CLARA, Calif.--(BUSINESS WIRE)--Ilypsa, Inc., a privately-held biopharmaceutical company pioneering novel non-absorbed drugs for renal disorders, announced today that it has completed enrollment of the company’s Phase 2 clinical trial of ILY101 in the United States. ILY101 is a novel phosphate binding agent for the treatment of hyperphosphatemia, a serious complication in patients with kidney disease on dialysis.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES